Journal article · 2026 · Open access

CRISPR/Cas based genome editing for liver diseases: Promise and challenge

Juan Guan, Min Yang, Xinyu Yang, Qin He, Bin Wang, Changyou Zhan

Acta Pharmaceutica Sinica B · Published 1 October 2026 · DOI 10.1016/j.apsb.2026.09.027

Open PDFView at the publisherCite this paper

In brief

“CRISPR/Cas based genome editing for liver diseases: Promise and challenge” is a 2026 journal article by Juan Guan and 5 co-authors, published in Acta Pharmaceutica Sinica B. OpenAlex counts 0 citations as of 17 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Acta Pharmaceutica Sinica B.

Citations
0
References
315
Authors
6

Abstract

Liver disorders pose a severe threat to public health and impose a substantial burden on global healthcare systems. In recent years, the Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated proteins (CRISPR/Cas) based genome editing technology has emerged as a promising approach for managing various liver pathologies. This review systematically summarizes the applications of these technologies in the treatment of liver diseases. We analyze the current development status of CRISPR/Cas based gene-editing tools and the available delivery systems, further summarize the latest research advances in the management of hereditary liver diseases, infectious liver diseases, and hepatocellular carcinoma (HCC), and finally discuss the challenges of CRISPR/Cas based editing for liver diseases management as well as the outlook derived from the above analysis. By integrating insights into both opportunities and obstacles, this review aims to provide a comprehensive framework to guide future research, subsequent clinical translation, and the rational application of CRISPR genome editing in liver disease management.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Guan, J., Yang, M., Yang, X., He, Q., Wang, B., & Zhan, C. (2026). CRISPR/Cas based genome editing for liver diseases: Promise and challenge. Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2026.09.027

MLA 9

Guan, Juan, et al. “CRISPR/Cas based genome editing for liver diseases: Promise and challenge.” Acta Pharmaceutica Sinica B, 2026. https://doi.org/10.1016/j.apsb.2026.09.027.

Chicago

Guan, Juan, Min Yang, Xinyu Yang, Qin He, Bin Wang, and Changyou Zhan. 2026. “CRISPR/Cas based genome editing for liver diseases: Promise and challenge.” Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2026.09.027.

Harvard

Guan, J. et al. (2026) ‘CRISPR/Cas based genome editing for liver diseases: Promise and challenge’, Acta Pharmaceutica Sinica B. doi:10.1016/j.apsb.2026.09.027.

IEEE

J. Guan, M. Yang, X. Yang, Q. He, B. Wang, and C. Zhan, “CRISPR/Cas based genome editing for liver diseases: Promise and challenge,” Acta Pharmaceutica Sinica B, 2026, doi: 10.1016/j.apsb.2026.09.027.

BibTeX

@article{guan2026crispr,
  title     = {{CRISPR/Cas based genome editing for liver diseases: Promise and challenge}},
  author    = {Guan, Juan and Yang, Min and Yang, Xinyu and He, Qin and Wang, Bin and Zhan, Changyou},
  journal   = {Acta Pharmaceutica Sinica B},
  year      = {2026},
  doi       = {10.1016/j.apsb.2026.09.027},
  url       = {https://doi.org/10.1016/j.apsb.2026.09.027}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering

  • CRISPR/Cas genome editing
  • liver disease
  • gene delivery systems
  • hereditary liver disease
  • infectious liver disease
  • hepatocellular carcinoma
  • gene therapy
  • clinical translation

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Guan, J., Yang, M., Yang, X., He, Q., Wang, B., & Zhan, C. (2026). CRISPR/Cas based genome editing for liver diseases: Promise and challenge. Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2026.09.027

How many times has this paper been cited?

0 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Acta Pharmaceutica Sinica B: sign in and open the PDF from this page.

Who wrote this paper?

Juan Guan, Min Yang, Xinyu Yang, Qin He, Bin Wang, Changyou Zhan.

What is the DOI of this paper?

10.1016/j.apsb.2026.09.027, permanently at https://doi.org/10.1016/j.apsb.2026.09.027. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.